For Immediate Release
Tanner Pharma Group
CHARLOTTE, N.C. – Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Nephcentric LLC (“Nephcentric”), a developer and marketer of evidence based therapeutic options for people with kidney disease and metabolic disorders. The agreement names Tanner as a distributor of ure-Na (Urea 15g) in areas outside of the United States, Canada, and the Middle East where the product is not yet registered. ure-Na (Urea 15g) is a Medical Food for the management of hyponatremia.
The distribution will be managed by TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner Pharma Group. TannerGAP offers turn key global access solutions for the distribution of products from markets of supply to markets of demand.
Maryori Alvarenga, Managing Director of US and Global Director for TannerGAP, commented, “We are excited to work with Nephcentric on a global level to provide ure-NA access to patients in need.”
Caroline Von Scheven, Operations Lead for Nephcentric, added, “We are looking forward to our partnership with Tanner to help expand our reach beyond North America. Our partnership with Tanner will help more patients in need gain access to our cost-effective, evidence-based therapeutic options”.
To obtain additional details about Global Access Programs, please contact a Tanner Pharma representative at +1 704 552 8408 or email email@example.com. For Nephcentric product related enquiries, please email firstname.lastname@example.org.
About Nephcentric LLC:
Nephcentric LLC focuses on cost effective, problem solving, needs-based therapeutic options for patients and physicians. Unlike a traditional biopharmaceutical company, which often relies on higher prices in the specialty space, Nephcentric relies on a lower cost, high efficiency model to bring ure-Na and other products to the medical marketplace. For more information, please visit www.nephcentric.com.
About Tanner Pharma Group
For over 16 years, Tanner Pharma Group has partnered with biopharmaceutical companies to provide turn-key commercialization solutions to increase patient access to medicines around the world. By partnering with Tanner Pharma, biotech and pharma companies are able to focus on their primary markets while ensuring that patients in international markets of need are receiving their products through a strictly controlled channel.
Tanner Pharma believes that access to medicines should have no borders and measures its value as a company based on the lives it helps to improve. With an unparalleled blend of local market knowledge, international supply chain expertise across more than 130 countries, and high regulatory compliance and quality standards, it provides tailored solutions to biopharmaceutical companies outside their core markets of focus.
Headquartered in the U.S., Tanner’s reach includes Europe, Northeast Asia, Southeast Asia, the Middle East, Australia, Canada and Latin America, including Brazil, Mexico, the Caribbean, Central America and all of South America.
For more information about Tanner Pharma Group, please visit www.tannerpharma.com.